<DOC>
	<DOCNO>NCT02242435</DOCNO>
	<brief_summary>In Phase III clinical trial , approximately 320 eligible patient OA knee receive Ampion™ 4 mL Saline 4 mL ( 1:1 ) administer three IA injection , 2 week apart Day 0 , Week 2 , Week 4 .</brief_summary>
	<brief_title>AP-008 Multiple Injection Study Evaluating Safety Efficacy Ampion Osteoarthritis</brief_title>
	<detailed_description>A total approximately 320 male female subject , age 40 85 year , OA knee pain , enrol randomized 1:1 across two study arm , receive three ( 3 ) IA injection either active drug ( Ampion™ 4 mL ) placebo injection Baseline ( Day 0 ) Weeks 2 4 confirm eligibility regard inclusion/exclusion criterion list . Enrollment Kellgren subject limit Kellgren III IV . There seven ( 7 ) in-clinic visit three ( 3 ) phone visit . Subjects receive three ( 3 ) IA injection active drug ( Ampion™ 4 mL ) placebo Baseline ( Day 0 ) Weeks 2 4 . Subjects also attend in-clinic visit Week 6 , Week 12 , Week 20 , Week 24 ( final assessment ) . Post-treatment follow-up telephone call make subject within 24 hour IA injection ( Baseline ( Day 0 ) Weeks 2 4 ) call document . The clinical effect treatment OA knee pain evaluate clinic visit Weeks 2 , 4 , 6 , 12 , 20 , 24 use Western Ontario McMaster Universities Arthritis Index ( WOMAC® ) osteoarthritis Index 3.1 ( pain subscore function subscore ) overall global severity assessment ( Subject 's Global Assessment [ PGA ] ) .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Able provide write informed consent participate study . Willing able comply study requirement instruction site study staff . Male female , 40 year 85 year old ( inclusive ) . Must ambulatory . Index knee must symptomatic great 6 month clinical diagnosis OA support radiological evidence ( xray ) acquire screen assessed central reader . Subjects must Kellgren Lawrence Grade III IV inclusion study . Moderate moderatelysevere OA pain index knee ( rating least 1.5 WOMAC® Index 3.1 5point Likert Pain Subscale ) assess screen confirm randomization . Moderate moderatelysevere OA pain index knee ( even chronic dos nonsteroidal antiinflammatory drug [ NSAID ] , change 4 week prior screen , been/are use ) . No analgesia take 24 hour efficacy measure . As result medical review screen investigation , Principal Investigator considers subject unfit study . Previous Ampion™ injection index knee . Known clinically significant liver abnormality ( e.g. , cirrhosis , transplant , etc ) . A history allergic reaction human albumin ( reaction nonhuman albumin egg albumin exclusion criterion ) . A history allergic reaction excipients 5 % human albumin ( Nacetyltryptophan , sodium caprylate ) . Presence tense effusion index knee . Inflammatory crystal arthropathy , acute fracture , history aseptic necrosis joint replacement index knee , assess locally Principal Investigator . Isolated patella femoral syndrome , also know chondromalacia , index knee . Any disease condition interfere free use evaluation index knee duration trial ( e.g. , cancer , congenital defect , spine OA ) . Major injury index knee within 12 month prior screen . Severe hip OA ipsilateral index knee . Any pain could interfere assessment index knee pain ( e.g. , pain part low extremity , pain radiate knee ) . Any pharmacological nonpharmacological treatment target OA start change 4 week prior treatment likely change duration study . Use follow medication exclusionary : IA inject pain medication study knee study ; Analgesics contain opioids . NSAIDs may continue level precede study acetaminophen available rescue medication study provide supply ; Topical treatment osteoarthritis index knee study ; Significant anticoagulant therapy ( e.g. , Heparin Lovenox ) study ( treatment Aspirin Plavix allow ) ; Systemic treatment may interfere safety efficacy assessment study ; Immunosuppressants ; Use corticosteroid &gt; 10 mg prednisolone equivalent per day ( ≤ 10 mg prednisolone , dose must stable ) . Any human albumin treatment 3 month randomization .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>